Wujood Khayat and Christian Lehmann

Published in Metabolites

 June 2022



Abnormal blood coagulation or coagulopathy is a common manifestation of many patholog- ical conditions. It occurs when there is an imbalance between the activities of the coagulation system and the fibrinolytic system, leading to excessive or impaired intravascular blood clot formation, which can disturb blood flow causing ischemia or hemorrhage in the affected tissues. A growing body of evidence has demonstrated blood coagulation abnormalities in association with cannabinoid use, suggesting the involvement of the endogenous cannabinoid system (ECS) in modulating blood coagulation. However, the evidence in the literature has been controversial on whether cannabinoids promote or inhibit blood coagulation. The ECS has been extensively studied in recent years for its potential as a therapeutic target for many diseases. This review provides a brief introduction to the ECS and discusses the reported anticoagulatory and procoagulatory effects of various cannabinoids, highlighting some possible mechanisms that might underlie the observed effects. Understanding the coagulatory effects of cannabinoids and the interaction between the coagulation system and the ECS is vital for developing novel therapeutics for coagulopathies.

Full Paper>>

DOI: 10.3390/metabo12060541



Citation: Khayat, W., & Lehmann, C. (2022). The Endocannabinoid System: A Potential Therapeutic Target for Coagulopathies. Metabolites, 12(6), 541.